Sunitinib
- Generic Name
- Sunitinib
- Brand Names
- Sutent, Sunitinib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C22H27FN4O2
- CAS Number
- 557795-19-4
- Unique Ingredient Identifier
- V99T50803M
- Background
Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formulation. Sunitinib inhibits cellular signaling by targeting multiple RTKs. These include all platelet-derived growth factor receptors (PDGF-R) and vascular endothelial growth factor receptors (VEGF-R). Sunitinib also inhibits KIT (CD117), the RTK that drives the majority of GISTs. In addition, sunitinib inhibits other RTKs including RET, CSF-1R, and flt3.
- Indication
Sunitinib is indicated for the following conditions:
- Associated Conditions
- Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
- Associated Therapies
- -
Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors
- Conditions
- Adult Solid NeoplasmClear Cell Renal Cell CarcinomaRecurrent Renal Cell CarcinomaStage III Renal Cell CancerStage IV Renal Cell Cancer
- Interventions
- Other: Computed TomographyOther: Fluorothymidine F-18Other: Laboratory Biomarker AnalysisOther: Pharmacological StudyOther: Positron Emission TomographyDrug: Sunitinib Malate
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 25
- Registration Number
- NCT00499135
- Locations
- 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
- Conditions
- Adult Anaplastic AstrocytomaAdult Giant Cell GlioblastomaAdult Mixed GliomaAdult GliosarcomaAdult Diffuse AstrocytomaAdult GlioblastomaAdult OligodendrogliomaAdult Pineal Gland Astrocytoma
- Interventions
- Drug: sunitinib malateOther: pharmacological study
- First Posted Date
- 2007-07-11
- Last Posted Date
- 2016-02-29
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 31
- Registration Number
- NCT00499473
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
A Phase I/II Study of Sunitinib and Dacarbazine
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 11
- Registration Number
- NCT00496223
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2012-10-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 204
- Registration Number
- NCT00495872
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Sunitinib Malate (SUO11248) In Subjects W/ Metastatic And/Or Surgically Unresectable Hepatocellular Cancers (HCC)
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2012-03-27
- Lead Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Target Recruit Count
- 33
- Registration Number
- NCT00495625
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in First-Line Patients With Metastatic Renal Cell Cancer (SABRE-R)
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2007-06-26
- Last Posted Date
- 2009-04-10
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00491738
Sunitinib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Ocular Melanoma
- Conditions
- Intraocular Melanoma
- First Posted Date
- 2007-06-21
- Last Posted Date
- 2014-01-10
- Target Recruit Count
- 50
- Registration Number
- NCT00489944
- Locations
- 🇺🇸
San Diego Pacific Oncology and Hematology Associates, Incorporated - Encinitas, Encinitas, California, United States
Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye Melanoma
- Conditions
- Malignant Conjunctival NeoplasmIntraocular Melanoma
- Interventions
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2017-03-27
- Lead Sponsor
- National Institutes of Health Clinical Center (CC)
- Target Recruit Count
- 12
- Registration Number
- NCT00482911
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
- Conditions
- Breast Cancer
- First Posted Date
- 2007-06-05
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- NCIC Clinical Trials Group
- Target Recruit Count
- 4
- Registration Number
- NCT00482755
- Locations
- 🇨🇦
British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Edmond Odette Cancer Centre at Sunnybrook, Toronto, Ontario, Canada
A Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2015-12-09
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 3
- Registration Number
- NCT00480935
- Locations
- 🇨🇦
University Health Network, Princess Margaret Hospital, Toronto, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.